Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 4/20 | 0.31 |
| ▸ | CNR2 | P34972 | 4/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21844027 | 1.00 | FPR2 (0.35) | FPR2PIK3CDPPARGPPARDPPARA | |
| SCHEMBL24946125 | 0.86 | FPR2 (0.34) | FPR2PIK3CDPPARGPPARDPPARA | |
| SCHEMBL21844018 | 0.81 | FPR2 (0.34) | FPR2PIK3CDPPARGPPARDPPARA | |
| SCHEMBL21844021 | 0.78 | USP2 (0.45) | CNR1MMP1MMP8ADAM17 | |
| SCHEMBL21916705 | 0.78 | FPR2 (0.33) | FPR2PIK3CDPPARGPPARDPPARA | |
| SCHEMBL21916707 | 0.78 | USP2 (0.45) | CNR1MMP1MMP8ADAM17 | |
| SCHEMBL10311712 | 0.76 | PIK3CD (0.42) | FPR2PIK3CDPPARGPPARDPPARA | |
| SCHEMBL25091293 | 0.74 | MMP1 (0.44) | MMP1MMP8ADAM17 | |
| SCHEMBL21917408 | 0.74 | MMP1 (0.44) | MMP1MMP8ADAM17 | |
| SCHEMBL1582483 | 0.74 | MEN1 (0.45) | FPR2PIK3CDPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11566001-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11566001-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | FPR2 4413/4885PIK3CD 1647/4885PPARG 2227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.